Takeda's QDENGA▼ (Dengue Tetravalent Vaccine [Live, A

08.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in ...

Related Keywords

Indonesia , Sri Lanka , Japan , Philippines , United States , Brazil , Colombia , Nicaragua , Germany , Thailand , Siyambalapitiya , Sabaragamuwa , Dominican Republic , Bulugahapitiya , Central , Italy , Panama , Spain , France , Berlin , America , Takeda Yakuhin Kogyo , Tomas Jelinek , World Health Organization , Berlin Centre For , Data Monitoring Committee , Exchange Commission , European Union Eu Member States , Takeda Pharmaceutical Company Limited , European Centre For Disease Prevention , Medical Director , Berlin Centre , Tropical Medicine , Scientific Director , Dengue Efficacy Study , Fiscal Year , European Union , Member States , Product Characteristics , Latin America , Rare Genetics , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report , Retrieved December , World Health , European Centre , Disease Prevention , Imported Infectious Diseases , Clinical Features , Imported Dengue Fever , Sentinel Surveillance Data , Clin Inf , Tourism Statistics , Tetravalent Dengue Vaccine Candidate , Northern European Conference , Travel Medicine , Tetravalent Dengue Vaccine , Healthy Children , Takeda Yakuhin Kogyo Stock ,